• Sign in
  • Sign up 
  • Welcome
  • FAQ
  • Switch to Night Mode
  • Stolen Accounts Recovery 
  • Change Account Password 
  • Vote for Witnesses 
  • Steem Proposals 
  • Developer Portal 
  • Steem Bluepaper 
  • SMT Whitepaper 
  • Steem Whitepaper 
  • Privacy Policy
  • Terms of Service
Homeby Witness Moecki
LoginSign up

Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% - MarketWatch

liesizigfa (38)in #dlike • 6 years ago

Shared From Dlike

Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had...


Source of shared Link

#dlike-news
6 years ago in #dlike by liesizigfa (38)
$0.00
  • Max accepted payout: $900.00
3 votes
  • + dlike
  • - mack-bot
  • - spaminator
Reply 0